%0 Journal Article %T Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia %A Kurata, Yu %A Tanaka, Tetsuhiro %A Nangaku, Masaomi %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia %K %X Prolyl hydroxylase domain (PHD) inhibitors are orally bioavailable small-molecule compounds that activate hypoxia inducible factor (HIF). HIF is a master transcription factor for regulating the cellular adaptive response to hypoxia. Erythropoietin (EPO), a hormone essential for red blood cell production, is one of the target genes of HIF. PHD inhibitors have been developed for the treatment of anemia with chronic kidney disease (CKD). %U https://atm.amegroups.org/article/view/30328 %P S334 %@ 2305-5847